Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion

Agios Pharmaceuticals (AGIO) stock jumps as the company plans to seek U.S. accelerated approval for a label expansion of its ...
InvestorsHub on MSN

Agios shares jump as FDA discussions advance mitapivat approval pathway

Agios Pharmaceuticals (NASDAQ:AGIO) shares climbed about 12% on Tuesday after the company reported progress toward a ...
pharmaphorum

Agios mulls early FDA filing for sickle cell therapy

Mitapivat has been approved in the US under the Pyrukynd trade name since 2022 as a treatment for haemolytic anaemia in ...
TMCnet

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway ; Company plans to submit mitapivat sNDA in sickle cell di ...
Seeking Alpha

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...
EurekAlert!

Discovery of key metabolic regulation mechanisms in cancer development

Researchers from the University of Seville have participated in research to identify the molecular details of the regulation of an enzyme essential for sugar metabolism and closely linked to cell ...
Medscape

Tumor M2 Pyruvate Kinase: A Tumor Marker and its Clinical Application in Gastrointestinal Malignancy

Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel tumor ...
EurekAlert!

ING5 inhibits aerobic glycolysis of lung cancer cells by promoting TIE1-mediated phosphorylation of pyruvate dehydrogenase kinase 1 at Y163

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis being the primary contributor to poor patient outcomes. A critical factor in ...